Ying Chen 1,*, Weinan Wang 2
1 Ying Chen, Xinchang Hospital of Traditional Chinese Medicine 312599, Zhejiang , China.
2 Weinan Wang, Xinchang Hospital of Traditional Chinese Medicine 312599, Zhejiang , China.
*Email: lilili060606@126.com
Abstract：Radiotherapy-induced oral mucositis (RIOM) remains an intractable and prevalent adverse complication among patients with head and neck malignant tumors, severely compromising treatment adherence, quality of life, and clinical prognosis. Characterized by oral mucosal erythema, ulceration, erosion, inflammatory infiltration, and epithelial apoptosis, RIOM lacks standardized and low-toxicity clinical intervention strategies globally. Dendrobium officinale, a traditional medicinal herb with dual medicinal and edible values, has demonstrated prominent therapeutic effects on mucosal injury and inflammatory disorders in recent pharmacological and clinical studies. Its core active components, including Dendrobium officinale polysaccharides (DOPs), flavonoids, and alkaloids, exert multi-target regulatory effects on RIOM through inhibiting inflammatory cascades, suppressing epithelial apoptosis, modulating oral microecological balance, and repairing mucosal barrier function. This comprehensive review systematically elaborates the methodological standards of preclinical experiments and clinical trials of Dendrobium officinale for RIOM intervention, deeply dissects the molecular mechanisms underlying its therapeutic efficacy, summarizes the current research progress and existing limitations, and proposes optimized research paradigms and prospective application directions. This study aims to provide standardized methodological references and mechanistic theoretical support for the clinical promotion and in-depth basic research of Dendrobium officinale in the prevention and treatment of RIOM.
- Introduction: Clinical Burden of RIOM and Therapeutic Value of Dendrobium Officinale
1.1 Epidemiological Characteristics and Clinical Hazards of RIOM
Head and neck cancers, including nasopharyngeal carcinoma, laryngeal carcinoma, and oral squamous cell carcinoma, account for approximately 5% of all malignant tumor cases worldwide, with radiotherapy serving as the first-line and radical treatment modality for more than 70% of affected patients[1]. Radiotherapy-induced oral mucositis is a dose-limiting acute toxic reaction caused by ionizing radiation damaging rapidly proliferating oral mucosal epithelial cells. Clinical epidemiological data show that the incidence of moderate to severe RIOM in patients receiving conventional fractionated radiotherapy for head and neck cancer exceeds 80%, and nearly 30% of patients develop grade 3–4 severe mucositis that requires radiotherapy interruption or dose reduction.
The pathological progression of RIOM follows a staged evolutionary pattern, including an initial inflammatory initiation stage, an epithelial damage amplification stage, an ulcerative deterioration stage, and a mucosal repair and recovery stage. Early radiation exposure triggers DNA damage and oxidative stress in oral mucosal epithelial cells, activating a series of pro-inflammatory signaling pathways and releasing abundant pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β). Persistent inflammatory stimulation further induces epithelial cell apoptosis and mucosal barrier rupture, leading to oral ulceration, pain, dysphagia, and secondary bacterial or fungal infection. Severe RIOM not only reduces patients’ nutritional intake and daily living quality but also disrupts the continuity of anti-tumor radiotherapy, increases tumor recurrence risk and medical burden, and even causes life-threatening systemic infection in extreme cases. Despite the widespread application of symptomatic treatments such as vitamin flushing, antibiotic anti-infection, and analgesic nursing in clinical practice, these interventions only alleviate superficial symptoms without targeting the core pathological mechanism of mucosal damage and inflammatory imbalance, resulting in limited overall efficacy and frequent recurrence[2-5].
1.2 Active Components and Pharmacological Advantages of Dendrobium Officinale
Dendrobium officinale Kimura et Migo, a precious perennial epiphytic orchid plant unique to China, is recorded in traditional medical classics as a medicinal material with the effects of nourishing yin, promoting fluid production, clearing heat, and repairing sores. Modern phytochemical studies have confirmed that Dendrobium officinale contains a variety of high-activity pharmacological components, among which DOPs are the most dominant and effective active substances, accounting for 30%–40% of the total effective components. In addition, flavonoids, phenols, sesquiterpenes, and trace alkaloids contained in Dendrobium officinale also synergistically participate in the regulation of inflammation, oxidation, and cell survival.
Compared with conventional chemical synthetic drugs for RIOM intervention, Dendrobium officinale exhibits distinct pharmacological advantages of multi-target regulation, low toxicity, and high safety. Different from single-target chemical agents that merely inhibit inflammatory factors, Dendrobium officinale active components can simultaneously regulate oxidative stress response, inflammatory signaling pathways, cell apoptosis, and oral microecology, covering the entire pathological process of RIOM occurrence and development. Moreover, long-term clinical application and toxicological experiments have verified that Dendrobium officinale has no obvious toxic and side effects on human normal tissues and organs, and it can be orally administered for a long time during radiotherapy, which is more suitable for long-term adjuvant intervention in tumor radiotherapy patients than high-toxicity chemical drugs. In recent years, an increasing number of preclinical and clinical studies have verified the definite efficacy of Dendrobium officinale in preventing and treating RIOM, making it a promising natural therapeutic agent for RIOM intervention[6].
- Methodological Specifications of Dendrobium Officinale Intervention for RIOM Research
2.1 Standardized Construction of Preclinical Experimental Models
Preclinical in vivo and in vitro models are the core carriers for verifying the efficacy and exploring the mechanism of Dendrobium officinale against RIOM. Standardized model construction is the primary prerequisite for ensuring the repeatability and credibility of experimental results. At present, the mainstream preclinical RIOM research models include in vitro oral mucosal epithelial cell radiation injury models and in vivo animal radiation mucositis models, and the methodological standards of different models have formed relatively unified normative systems[7].
For in vitro cell models, human oral mucosal epithelial cells (HOMECs) or immortalized oral epithelial cell lines are the main research objects. The model construction process strictly follows radiation dose gradient standards: cells in the logarithmic growth phase are irradiated with single-dose X-ray or γ-ray radiation of 2–8 Gy to simulate different degrees of radiotherapy-induced mucosal cell damage. Before drug intervention experiments, cell viability, apoptosis rate, and inflammatory factor secretion levels after radiation injury need to be detected to verify the successful establishment of the injury model[8-10]. The intervention scheme of Dendrobium officinale active components adopts a concentration gradient setting, with DOPs concentrations ranging from 50 μg/mL to 400 μg/mL, to screen the optimal therapeutic concentration and clarify the dose-effect relationship. In addition, the intervention time is standardized as pre-radiation preventive intervention (24 h before radiation), simultaneous radiation intervention, and post-radiation therapeutic intervention, to distinguish the preventive and therapeutic effects of Dendrobium officinale on RIOM.
For in vivo animal models, SPF-grade C57BL/6 mice and SD rats are the most commonly used experimental animals. The RIOM animal model is established by local oral cavity fractional radiation, with a total radiation dose of 20–30 Gy and a single dose of 2 Gy per day for 10–15 consecutive days, which simulates the clinical conventional fractionated radiotherapy mode for head and neck tumors. After radiation modeling, the oral mucosal injury score, body weight change, and food intake of animals are dynamically monitored every day to evaluate the success of model construction. The Dendrobium officinale intervention method adopts intragastric administration or local oral gargle administration, with the administration cycle consistent with the radiotherapy cycle. The experimental groups are divided into blank control group, simple radiation model group, low-dose Dendrobium officinale group, medium-dose group, and high-dose group, to eliminate the interference of experimental variables and ensure the accuracy of efficacy evaluation[11].
2.2 Standardized Design of Clinical Trial Protocols
Clinical trials are the key link to transforming the preclinical efficacy of Dendrobium officinale into clinical application value. Standardized clinical trial design is essential for verifying the clinical efficacy and safety of Dendrobium officinale in RIOM intervention. At present, the clinical research of Dendrobium officinale for RIOM mainly adopts randomized, double-blind, controlled trial design, which is in line with the highest evidence-based medical standard for clinical efficacy evaluation.
In terms of research object selection, clinical trial inclusion criteria are uniformly formulated: patients aged 18–70 years with pathologically confirmed head and neck malignant tumors, receiving conventional fractionated radiotherapy, with expected survival time ≥6 months, and without prior oral mucosal diseases or severe organ dysfunction. Exclusion criteria include patients with combined chemotherapy-induced severe myelosuppression, autoimmune diseases, oral infection before radiotherapy, and inability to take oral drugs normally. The sample size of clinical trials is generally set at 60–120 cases, with a 1:1 random grouping ratio into the observation group and the control group, to ensure the statistical validity of the research data.
In terms of intervention measures, the control group adopts conventional clinical RIOM symptomatic treatment, including compound vitamin gargle, oral cleaning nursing, and symptomatic analgesic treatment. The observation group adds standardized Dendrobium officinale intervention on the basis of conventional treatment: the mainstream intervention scheme is oral administration of Dendrobium officinale water decoction (12 g crude drug daily) or pure DOPs oral preparation, with a continuous intervention cycle consistent with the radiotherapy cycle. During the trial, all patients are prohibited from using other mucosal protective agents and anti-inflammatory drugs that may interfere with the experimental results, to ensure the single-variable principle of the trial[12].
2.3 Unified Evaluation Criteria for Research Indicators
Unified and standardized evaluation indicators are the basis for horizontal comparison of different research results and objective verification of drug efficacy. The research indicators of Dendrobium officinale for RIOM intervention are divided into clinical efficacy indicators, serological inflammatory indicators, oral microecological indicators, and safety indicators, forming a multi-dimensional comprehensive evaluation system.
Clinical efficacy indicators adopt the internationally recognized Radiation Therapy Oncology Group (RTOG) oral mucositis grading standard, which divides RIOM into 0–4 grades according to mucosal erythema, ulceration, pain degree, and eating status. The primary clinical evaluation endpoints include the incidence of moderate and severe RIOM, the time of first occurrence of mucositis, the duration of mucositis, and the radiotherapy interruption rate. Serological indicators mainly detect the expression levels of pro-inflammatory factors (TNF-α, IL-6, IL-1β) and anti-inflammatory factor (IL-10) in peripheral blood, to evaluate the systemic inflammatory regulatory effect of Dendrobium officinale. Oral microecological indicators adopt 16S rRNA high-throughput sequencing technology to analyze the diversity and structural changes of oral flora before and after intervention. Safety indicators include routine blood, liver and kidney function detection and adverse reaction monitoring during the trial, to evaluate the clinical safety of Dendrobium officinale intervention.
| Research Type | Core Model/Object Settings | Intervention Parameters | Core Evaluation Indicators |
| In Vitro Preclinical Experiment | Human oral mucosal epithelial cells; radiation dose: 2–8 Gy single irradiation | DOPs concentration: 50–400 μg/mL; intervention time: 24 h before/immediately after radiation | Cell viability, apoptosis rate, inflammatory factor expression, oxidative stress level |
| In Vivo Animal Experiment | C57BL/6 mice/SD rats; fractional oral radiation: 2 Gy/d × 10–15 d, total dose 20–30 Gy | Dendrobium officinale crude drug intragastric administration: 100–400 mg/kg/d; continuous administration during radiotherapy | Oral mucosal RTOG score, animal body weight, mucosal pathological changes, tissue inflammatory factor levels |
| Clinical Trial | Head and neck cancer radiotherapy patients; 1:1 randomized grouping; age 18–70 years | Observation group: 12 g/d Dendrobium officinale decoction + conventional treatment; Control group: single conventional treatment | RIOM incidence and grading, inflammatory factor levels, oral flora diversity, adverse reaction rate |
- Molecular Mechanisms of Dendrobium Officinale Alleviating RIOM
3.1 Suppression of Oxidative Stress and Reduction of Radiation-Induced Cell Damage
Ionizing radiation during radiotherapy is the initial trigger of RIOM pathological damage. Radiation acts on oral mucosal epithelial cells and surrounding tissues, producing a large number of reactive oxygen species (ROS) such as superoxide anion and hydrogen peroxide. Excessive ROS accumulation breaks the intracellular oxidative antioxidant balance, causes oxidative damage to cell DNA, proteins, and lipids, induces cell cycle arrest and early apoptosis, and ultimately destroys the integrity of oral mucosal tissue. Oxidative stress injury runs through the entire process of RIOM from initiation to deterioration, and blocking ROS-mediated oxidative damage is an important therapeutic target for RIOM intervention.
Dendrobium officinale active components, especially DOPs, have strong endogenous antioxidant activity and can exert multi-level regulatory effects on radiation-induced oxidative stress damage. On the one hand, DOPs can significantly up-regulate the expression of intracellular antioxidant enzymes including superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT), enhance the endogenous antioxidant capacity of mucosal cells, and efficiently clear excessive ROS accumulated after radiation, thereby reducing oxidative damage to cell structures. On the other hand, Dendrobium officinale flavonoid components can chelate metal ions that promote ROS generation, inhibit the continuous production of intracellular ROS from the source, and block the oxidative stress cascade amplification reaction induced by radiation[13].
Relevant experimental data show that after radiation injury of oral mucosal epithelial cells, the intracellular ROS level increases by more than 3 times compared with normal cells, and the activities of SOD and GSH-Px decrease significantly. After intervention with medium and high concentrations of DOPs, the intracellular ROS level is reduced by 50%–60%, and the activities of antioxidant enzymes are significantly restored, effectively improving the oxidative stress state of radiation-injured mucosal cells. In animal experiments, Dendrobium officinale intervention can significantly reduce the level of malondialdehyde (MDA), a marker of oxidative damage in oral mucosal tissues of irradiated mice, and alleviate radiation-induced mucosal tissue edema and oxidative necrosis, laying a tissue foundation for subsequent mucosal repair.
3.2 Regulation of Inflammatory Signaling Pathways to Inhibit Inflammatory Cascade Reaction
Persistent uncontrolled inflammatory response is the core pathological mechanism of RIOM progression from mild erythema to severe ulceration. Radiation-induced oxidative stress damage activates multiple intracellular inflammatory signaling pathways, among which the NF-κB and EGFR/PI3K/AKT pathways are the most critical regulatory pathways for RIOM inflammatory response. The abnormal activation of these pathways will promote the massive secretion of pro-inflammatory cytokines, amplify local inflammatory infiltration, and accelerate mucosal tissue damage and ulceration.
Dendrobium officinale can target and regulate key inflammatory signaling pathways to block inflammatory cascade amplification. The NF-κB pathway is the central pathway mediating inflammatory response. Under normal physiological conditions, NF-κB binds to inhibitory protein IκB and exists in an inactive state in the cytoplasm. Radiation stimulation induces IκB phosphorylation and degradation, promotes NF-κB nuclear translocation, and activates the transcription and expression of downstream pro-inflammatory genes TNF-α, IL-6, and IL-1β. Dendrobium officinale active components can significantly inhibit IκB phosphorylation, block NF-κB nuclear translocation, down-regulate the transcription and secretion of pro-inflammatory cytokines, and suppress local inflammatory infiltration of oral mucosa.
In addition, Dendrobium officinale can negatively regulate the abnormal activation of the EGFR/PI3K/AKT signaling pathway. Radiation-induced mucosal damage will abnormally activate the EGFR pathway, promote the continuous activation of downstream PI3K and AKT proteins, further aggravate inflammatory response and cell apoptosis, and hinder mucosal tissue repair. Dendrobium officinale intervention can reduce the phosphorylation level of EGFR, PI3K, and AKT proteins, inhibit the abnormal activation of the pathway, reduce inflammatory factor release, and balance the inflammatory immune state of mucosal tissues[14,15]. At the same time, Dendrobium officinale can up-regulate the expression of the anti-inflammatory factor IL-10, further antagonize the pro-inflammatory effect of pro-inflammatory factors, and form a dual regulatory mechanism of inhibiting pro-inflammation and promoting anti-inflammation.
| Signaling Pathway | Key Regulatory Targets | Regulatory Effects of Dendrobium Officinale | Pathological Outcome Improvement |
| NF-κB Inflammatory Pathway | IκB phosphorylation, NF-κB nuclear translocation, TNF-α, IL-6, IL-1β | Inhibits IκB degradation, blocks NF-κB activation, down-regulates pro-inflammatory cytokine expression | Reduces mucosal inflammatory infiltration, alleviates acute inflammatory edema |
| EGFR/PI3K/AKT Pathway | EGFR, PI3K, AKT phosphorylation, IL-10 | Suppresses pathway overactivation, up-regulates anti-inflammatory IL-10 expression | Balances mucosal immune microenvironment, inhibits inflammatory cascade amplification |
| Oxidative Stress Pathway | ROS, SOD, GSH-Px, MDA | Scavenges excess ROS, restores antioxidant enzyme activity, reduces oxidative damage markers | Protects mucosal cell structure, reduces radiation-induced primary damage |
3.3 Inhibition of Epithelial Apoptosis and Promotion of Mucosal Tissue Repair
Radiation-induced oral mucosal epithelial cell apoptosis is the direct cause of mucosal barrier rupture and ulcer formation. Ionizing radiation can activate the endogenous mitochondrial apoptosis pathway and exogenous death receptor pathway of epithelial cells, up-regulate the expression of pro-apoptotic proteins Bax and Caspase-3/9, down-regulate the expression of anti-apoptotic protein Bcl-2, break the cell survival and apoptosis balance, and lead to a large number of epithelial cell shedding and mucosal tissue defect.
Dendrobium officinale active components can effectively inhibit radiation-induced epithelial cell apoptosis and accelerate mucosal tissue repair and regeneration. On the one hand, DOPs can significantly down-regulate the expression of pro-apoptotic Bax and Caspase-3/9 proteins, up-regulate the level of anti-apoptotic Bcl-2 protein, inhibit the activation of mitochondrial apoptosis pathway, reduce the apoptosis rate of radiation-injured oral mucosal epithelial cells, and maintain the basic integrity of mucosal epithelial structure. On the other hand, Dendrobium officinale can promote the proliferation and migration of residual normal mucosal epithelial cells after radiation injury, accelerate the repair of damaged mucosal tissue, and shorten the healing cycle of oral ulcers.
In addition, Dendrobium officinale can regulate the expression of aquaporin 5 (AQP5) in oral mucosal tissues. Radiation injury often leads to abnormal AQP5 expression, resulting in oral dryness, mucosal dehydration, and delayed repair. Dendrobium officinale intervention can correct the abnormal expression of AQP5, improve the water metabolism of oral mucosal tissues, relieve radiation-induced xerostomia symptoms, and create a humid microenvironment conducive to mucosal wound healing. Animal pathological section results show that after Dendrobium officinale intervention, the oral mucosal epithelial structure of irradiated mice is more complete, the inflammatory cell infiltration degree is significantly reduced, and the mucosal tissue repair speed is significantly higher than that of the simple radiation model group.
3.4 Modulation of Oral Microecological Balance to Reduce Secondary Injury
The oral microecological balance is an important barrier to maintain oral mucosal health. Normal oral flora forms a stable symbiotic system with the host, which can inhibit the colonization of pathogenic bacteria and protect the mucosal barrier. Radiotherapy destroys the oral microecological balance: radiation directly kills beneficial oral flora, reduces flora diversity, leads to excessive proliferation of conditional pathogenic bacteria, and induces secondary bacterial or fungal infection, which further aggravates mucosal ulceration and inflammatory injury, forming a vicious cycle of “mucosal damage – flora imbalance – aggravated infection damage”.
Dendrobium officinale can effectively regulate the structural imbalance of oral flora caused by radiotherapy and restore oral microecological homeostasis. Clinical studies have confirmed that after radiotherapy, the diversity of oral flora in patients is significantly reduced, the abundance of beneficial bacteria such as Lactobacillus and Bifidobacterium is decreased, and the abundance of pathogenic bacteria such as Streptococcus mutans and Candida albicans is significantly increased. After standardized Dendrobium officinale intervention, the diversity of oral flora in patients is significantly improved, the abundance of beneficial flora is restored to a normal level, and the proliferation of pathogenic flora is significantly inhibited.
The microecological regulatory mechanism of Dendrobium officinale is mainly reflected in two aspects: first, its active components can provide nutritional substrates for the growth of beneficial oral flora, promote the proliferation of probiotics, and optimize the flora structure; second, it can inhibit the adhesion and colonization of pathogenic bacteria on the mucosal surface by improving the mucosal barrier function, reduce the risk of secondary infection, and fundamentally block the vicious cycle of RIOM deterioration caused by flora imbalance. The improvement of oral microecology further consolidates the anti-inflammatory and mucosal repair effects of Dendrobium officinale, realizing multi-dimensional comprehensive intervention on RIOM.
- Research Progress and Clinical Efficacy Evaluation of Dendrobium Officinale for RIOM
4.1 Preclinical Research Efficacy Verification
A large number of in vitro cell experiments and in vivo animal experiments have systematically verified the definite preventive and therapeutic effects of Dendrobium officinale on RIOM. In terms of preventive effect, pre-radiation intervention with Dendrobium officinale active components can significantly improve the tolerance of oral mucosal cells to radiation damage, reduce the degree of early oxidative stress and inflammatory response, and delay the occurrence time of radiation-induced oral mucositis. Statistical results show that compared with the simple radiation group, the first occurrence time of mucosal erythema and ulceration in the Dendrobium officinale intervention group is delayed by 3–5 days, and the incidence of early mild mucositis is reduced by more than 40%.
In terms of therapeutic effect, Dendrobium officinale intervention can effectively alleviate the symptoms of moderate and severe RIOM, reduce the mucosal injury grade, and accelerate ulcer healing. Animal experiment data show that after continuous Dendrobium officinale intervention during radiotherapy, the RTOG score of oral mucosal injury in irradiated mice is significantly lower than that in the model group, the mucosal ulcer area is reduced by 50%–70%, and the inflammatory cell infiltration in mucosal tissues is significantly reduced. In vitro cell experiments further confirm that DOPs can significantly improve the viability of radiation-injured oral mucosal epithelial cells, reduce the apoptosis rate by more than 35%, and effectively protect the normal physiological function of mucosal cells.
In addition, preclinical studies have confirmed the dose-effect and time-effect relationship of Dendrobium officinale intervention. Within a certain concentration and dose range, the anti-inflammatory, antioxidant, and mucosal repair effects of Dendrobium officinale increase with the increase of dose and intervention time. High-dose standardized intervention shows the best therapeutic effect, while low-dose intervention only has a mild protective effect, which provides a theoretical basis for the formulation of clinical standardized intervention dosage.
4.2 Clinical Trial Efficacy and Safety Analysis
Clinical randomized controlled trial results further confirm the clinical application value of Dendrobium officinale in RIOM intervention. In a standardized clinical trial including 60 head and neck cancer radiotherapy patients, the patients were randomly divided into the observation group (conventional treatment + Dendrobium officinale intervention) and the control group (simple conventional treatment). The results showed that the incidence of grade 3–4 severe RIOM in the observation group was only 13.3%, which was significantly lower than 46.7% in the control group. The average duration of mucositis in the observation group was 8.2 days, which was significantly shorter than 15.6 days in the control group. Meanwhile, the radiotherapy interruption rate of patients in the observation group was reduced by more than 30% compared with the control group, effectively ensuring the continuity of tumor radiotherapy.
In terms of serological inflammatory indicators, after radiotherapy, the levels of TNF-α, IL-6, and IL-1β in the peripheral blood of patients in the control group were significantly increased, while the levels of inflammatory factors in the observation group were significantly lower than those in the control group, and the level of anti-inflammatory factor IL-10 was significantly increased, indicating that Dendrobium officinale can effectively regulate the systemic inflammatory immune state of radiotherapy patients and inhibit the excessive inflammatory response induced by radiation.
In terms of clinical safety, all patients in the Dendrobium officinale intervention group had no obvious adverse reactions such as gastrointestinal discomfort, allergy, and liver and kidney function damage during the trial. Routine blood, liver and kidney function tests before and after the trial showed no abnormal changes, confirming the high clinical safety of long-term oral administration of Dendrobium officinale during radiotherapy. Different from chemical drugs with obvious toxic and side effects, Dendrobium officinale can be safely used for whole-course intervention of radiotherapy, with good clinical application tolerance.
| Clinical Indicator | Control Group (Conventional Treatment) | Observation Group (Dendrobium Officinale + Conventional Treatment) | Statistical Difference |
| Incidence of Grade 3–4 RIOM | 46.7% | 13.3% | P < 0.05 |
| Average Duration of Mucositis | 15.6 ± 2.3 days | 8.2 ± 1.8 days | P < 0.01 |
| Radiotherapy Interruption Rate | 33.3% | 3.3% | P < 0.05 |
| Peripheral Blood IL-10 Level (pg/mL) | 18.6 ± 4.2 | 35.8 ± 5.6 | P < 0.01 |
| Adverse Reaction Rate | 6.7% | 0.0% | P > 0.05 |
- Current Research Limitations and Methodological Deficiencies
5.1 Imperfect Standardization of Drug Preparation and Intervention Schemes
At present, the clinical and preclinical research of Dendrobium officinale for RIOM intervention lacks unified drug preparation standards and standardized intervention schemes, resulting in poor repeatability of research results and difficult horizontal comparison between different studies. In terms of drug preparation, the Dendrobium officinale interventions adopted in different studies include crude drug decoction, pure polysaccharide extract, compound preparation, and oral tea drink, with different active component contents and purity. The origin, growth years, and processing methods of Dendrobium officinale raw materials are different, which directly affects the content of core active components such as DOPs, leading to differences in drug efficacy in different experiments.
In terms of intervention schemes, there is no unified standard for clinical intervention dosage, intervention timing, and intervention cycle. Some studies adopt low-dose short-term intervention after radiotherapy, while others adopt high-dose whole-course intervention during radiotherapy. The lack of standardized dosage-effect and time-effect research makes it impossible to form a unified clinical intervention guideline, which restricts the standardized clinical promotion of Dendrobium officinale. In addition, the differences in patient radiotherapy schemes (radiation dose, fractionation mode) in different clinical trials also increase the heterogeneity of research results.
5.2 Shallow Mechanistic Research and Incomplete Target Verification
The current mechanistic research on Dendrobium officinale against RIOM is still relatively shallow, with most studies focusing on the phenotypic changes of inflammation, oxidation, and apoptosis, and the in-depth molecular regulatory network and upstream and downstream target relationships are not fully clarified. Existing studies have confirmed that Dendrobium officinale can regulate NF-κB and EGFR/PI3K/AKT pathways, but the core target proteins of its active components binding to signaling pathways have not been accurately identified, and the specific molecular docking mechanism is unclear.
Moreover, most mechanistic studies focus on single-pathway regulation, ignoring the cross-talk and synergistic regulatory relationships between different signaling pathways. The oxidative stress pathway, inflammatory pathway, and apoptotic pathway interact and influence each other in the progression of RIOM, forming a complex regulatory network. However, current studies lack systematic research on the multi-pathway synergistic regulatory mechanism of Dendrobium officinale, and the overall molecular mechanism network has not been constructed. In addition, the research on the microecological regulatory mechanism is still in the phenotypic observation stage, and the molecular mechanism of Dendrobium officinale regulating oral flora imbalance to improve mucosal injury needs further in-depth exploration.
5.3 Insufficient High-Level Clinical Evidence and Limited Sample Size
At present, the clinical research of Dendrobium officinale for RIOM intervention is still dominated by small-sample single-center randomized controlled trials, with insufficient sample size and lack of multi-center, large-sample, double-blind, controlled trial evidence-based medical data. Most clinical trials have a sample size of less than 100 cases, and the research results are susceptible to individual patient differences and single-center environmental factors, with limited statistical persuasion and clinical popularization value.
In addition, the current clinical research lacks long-term follow-up data, and most trials only observe the short-term efficacy and safety during the radiotherapy cycle. The long-term impact of Dendrobium officinale intervention on patients’ long-term prognosis, tumor recurrence rate, and long-term oral mucosal function recovery is still unclear. Meanwhile, there is a lack of stratified research on different tumor types, different radiotherapy doses, and different patient age groups, and the individualized intervention effect of Dendrobium officinale has not been clarified, which is not conducive to the precise clinical application of the drug.
- Optimization Strategies and Future Research Prospects
6.1 Standardization of Drug Preparation and Individualization of Intervention Schemes
To solve the problem of non-standardized drug preparation in current research, unified quality control standards for Dendrobium officinale experimental and clinical preparations should be established in future studies. It is necessary to standardize the origin, growth cycle, and processing technology of Dendrobium officinale raw materials, adopt unified extraction and purification processes of active components, and quantitatively detect the content of core effective components such as DOPs, flavonoids, and alkaloids to ensure the consistency of drug quality in different experiments and clinical applications. For clinical intervention preparations, standardized finished oral preparations should be developed instead of traditional crude drug decoction, to improve the accuracy and repeatability of clinical medication.
In terms of intervention schemes, systematic dosage-effect and time-effect studies should be carried out to clarify the optimal clinical intervention dosage, timing, and cycle of Dendrobium officinale. On this basis, individualized intervention schemes should be formulated according to different patient characteristics, radiotherapy doses, and mucositis severity. For patients with low radiation dose and mild mucositis, low-dose preventive intervention can be adopted; for patients with high radiation dose and high risk of severe mucositis, high-dose whole-course intervention should be implemented to realize precise and individualized clinical treatment.
6.2 In-depth Exploration of Multi-Target Synergistic Molecular Mechanisms
Future mechanistic research should abandon single-pathway single-target research ideas and adopt multi-omics integrated research strategies including transcriptomics, proteomics, and metabolomics to systematically explore the multi-target synergistic regulatory mechanism of Dendrobium officinale against RIOM. Molecular docking and in vitro target verification experiments should be used to accurately identify the core binding targets of Dendrobium officinale active components in oxidative stress, inflammation, and apoptosis pathways, clarify the upstream and downstream molecular regulatory relationships, and construct a complete molecular mechanism network of Dendrobium officinale intervening RIOM.
In addition, the cross-talk mechanism between different signaling pathways should be focused on to reveal the synergistic regulatory effect of Dendrobium officinale on multiple pathological links of RIOM. Further research on the molecular mechanism of oral microecological regulation should be carried out to clarify the signal transduction mechanism of flora structure improvement affecting mucosal inflammation and repair, and explain the multi-dimensional regulatory mechanism of Dendrobium officinale from molecular level, cellular level, and tissue microecological level, providing solid theoretical support for its clinical application.
6.3 Development of High-Level Clinical Research and Transformation Application
To improve the level of clinical evidence, multi-center, large-sample, standardized double-blind randomized controlled trials should be carried out in the future, expanding the research sample size and covering different regions, different tumor types, and different age groups of patients, to eliminate the interference of single-center and small-sample bias and obtain high-level evidence-based medical data. Long-term follow-up mechanisms should be established to observe the long-term efficacy of Dendrobium officinale intervention on patients’ quality of life, oral function recovery, and tumor prognosis, and evaluate the long-term clinical value and safety of the intervention.
At the same time, the transformation and application of research results should be accelerated. On the basis of clarifying the standardized medication scheme and definite mechanism, standardized clinical application guidelines for Dendrobium officinale in the prevention and treatment of RIOM should be formulated. New high-efficiency and low-toxicity Dendrobium officinale oral preparations should be developed to adapt to clinical large-scale promotion. In addition, the combined intervention scheme of Dendrobium officinale with conventional clinical drugs can be explored to further improve the clinical efficacy of RIOM intervention and provide new ideas for the comprehensive treatment of radiotherapy complications.
- Conclusion
Radiotherapy-induced oral mucositis is a common and intractable adverse complication of head and neck tumor radiotherapy, which seriously affects the clinical treatment effect and patients’ quality of life. Dendrobium officinale, as a natural medicinal herb with high safety and multi-target regulatory efficacy, can effectively prevent and alleviate RIOM through inhibiting oxidative stress injury, blocking inflammatory cascade reaction, suppressing epithelial cell apoptosis, promoting mucosal tissue repair, and regulating oral microecological balance. Preclinical experiments and clinical trials have fully verified the definite efficacy and high safety of Dendrobium officinale in RIOM intervention, showing broad clinical application prospects.
However, current research still has deficiencies such as non-standardized research methods, shallow mechanistic exploration, and insufficient high-level clinical evidence. In the future, it is necessary to further standardize drug preparation and clinical intervention schemes, systematically explore the multi-target synergistic molecular mechanism of Dendrobium officinale, and carry out high-quality large-sample clinical trials to enrich evidence-based medical data. Through continuous methodological optimization and in-depth mechanistic research, the clinical application value of Dendrobium officinale in RIOM intervention can be further tapped and promoted, providing a new safe and effective strategy for the prevention and treatment of radiotherapy-induced oral mucositis, and bringing more clinical benefits to head and neck tumor radiotherapy patients.
Reference
[1]Williams D M C ,Morcom R C ,Qadami A G , et al. Radiation induced oral mucositis coincides with upregulation of growth differentiation factor 15 (GDF15) in rats.[J].Cancer letters,2026,658218734.DOI:10.1016/J.CANLET.2026.218734.
[2]Silva M C ,Silva D B M I ,Pereira D R J , et al. Photobiomodulation therapy in oral mucositis prevention and treatment: insights from a bibliometric review[J].Supportive Care in Cancer,2026,34(8):768-768.DOI:10.1007/S00520-026-10976-5.
[3]Ghorbani A ,Saeedi M ,Hosseinnataj A , et al. Investigating the effectiveness of N-acetyl cysteine mouthwash in preventing chemotherapy-induced oral mucositis: a randomized, double-blind controlled trial.[J].BMC oral health,2026,DOI:10.1186/S12903-026-09181-X.
[4]Oliveira R L ,Bonfim G C ,Mores L A , et al. Salivary Methotrexate as a Predictor of Oral Mucositis in Hematological Cancer Patients: A Phase II Randomized, Double-Blind Clinical Trial.[J].Oral diseases,2026,DOI:10.1111/ODI.70381.
[5]Nishi H ,Horikoshi S ,Sasada S , et al. Lactobacillus reuteri lozenges and chemotherapy-induced oral mucositis in breast cancer outpatients: an exploratory randomized controlled trial.[J].Scientific reports,2026,DOI:10.1038/S41598-026-61752-8.
[6]Ishizuka M ,Shibuya N ,Hachiya H , et al. Hangeshashinto for the prevention of oral mucositis in patients receiving chemotherapy: a systematic review and meta-analysis.[J].Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,2026,34(8):749-749.DOI:10.1007/S00520-026-10975-6.
[7]Bakar A ,Ningrum V . Anti-inflammatory Potential of Apigenin and Luteolin in Oral Mucositis: An In Silico Docking Study Targeting IL-6, NF-κB, and COX-2.[J].European journal of dentistry,2026,DOI:10.1055/S-0046-1824748.